BrainStorm Cell Therapeutics Says On July 18, Received MVLS Deficiency Notice From Nasdaq Listing Qualifications Department Staff
Portfolio Pulse from Benzinga Newsdesk
BrainStorm Cell Therapeutics announced that on July 18, it received a Minimum Value of Listed Securities (MVLS) deficiency notice from the Nasdaq Listing Qualifications Department staff.
July 19, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BrainStorm Cell Therapeutics received a Minimum Value of Listed Securities (MVLS) deficiency notice from Nasdaq, which could lead to potential delisting if not addressed.
Receiving an MVLS deficiency notice from Nasdaq indicates that BrainStorm Cell Therapeutics is not meeting the minimum value requirements for listed securities. This could lead to potential delisting if the issue is not resolved, which is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100